NCT02504996

Brief Summary

Siatalgia is one of the main symptoms related to emergency department presentations. Patients with sciatalgia are seeking for immediate pain relief and little known regarding the pain management of these patients in emergency department. This study aim to trial the effect of intravenous paracetamol and morphine in patients presented with sciatalgia to emergency department.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
300

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Jan 2015

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2015

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

July 2, 2015

Completed
20 days until next milestone

First Posted

Study publicly available on registry

July 22, 2015

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2016

Completed
Last Updated

July 22, 2015

Status Verified

July 1, 2015

Enrollment Period

1.2 years

First QC Date

July 2, 2015

Last Update Submit

July 21, 2015

Conditions

Keywords

sciatalgiaemergency departmentparacetamolmorphine

Outcome Measures

Primary Outcomes (1)

  • Visual Analogue Scale Score to measure pain reduction

    Visual Analogue Scale Score at 30 minutes in order to measure pain reduction

    30 minutes

Secondary Outcomes (2)

  • Rescue drug need questionnaire

    30 minutes

  • Adverse effects

    30 minutes

Study Arms (3)

Paracetamol

ACTIVE COMPARATOR

1 g intravenous paracetamol (Perfalga, Bristol Myers) in 100 ml saline with a rapid infusion.

Drug: Paracetamol

morphine

ACTIVE COMPARATOR

0.1 mg/kg morphine in 100 ml saline with a rapid infusion.

Drug: morphine

placebo

PLACEBO COMPARATOR

100 ml saline

Drug: Placebo

Interventions

1 g paracetamol via intravenous route in 100 ml normal saline

Also known as: Perfalgan
Paracetamol

0.1 mg/kg morphine via intravenous route in 100 ml normal saline

Also known as: Morfin
morphine

Intravenous 100 ml normal saline

placebo

Eligibility Criteria

Age21 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with pain radiating to the sciatic nerve path
  • Pain within the last one week
  • Patients with positive straight leg raise
  • Patients over 21 and lower than 65 years old

You may not qualify if:

  • Pain score lower than 40 mm in visual analogue scale score
  • Neurological deficit
  • Allergy to the study drugs
  • Unstable vital signs
  • History of malignancy or rheumatological diseases or arthritis
  • History of chronic pain syndrome
  • Receiving pain killer, steroid, anti-depressant, anti-convulsant and musculorelaxant within the last six hours.
  • Drug or alcohol addiction
  • Pregnancy or breast feeding
  • Fewer more than 37.9 Celsius degrees.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Pamukkale University Hospital

Denizli, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

SciaticaEmergencies

Interventions

AcetaminophenMorphine

Condition Hierarchy (Ancestors)

Sciatic NeuropathyMononeuropathiesPeripheral Nervous System DiseasesNeuromuscular DiseasesNervous System DiseasesNeuralgiaPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsDisease AttributesPathologic Processes

Intervention Hierarchy (Ancestors)

AcetanilidesAnilidesAmidesOrganic ChemicalsAniline CompoundsAminesMorphine DerivativesMorphinansOpiate AlkaloidsAlkaloidsHeterocyclic CompoundsHeterocyclic Compounds, Bridged-RingHeterocyclic Compounds, 4 or More RingsHeterocyclic Compounds, Fused-RingPhenanthrenesPolycyclic Aromatic HydrocarbonsPolycyclic Compounds

Study Officials

  • Mustafa Serinken, MD

    Pamukkale University

    STUDY CHAIR

Central Study Contacts

Mustafa Serinken, MD

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Proffesor

Study Record Dates

First Submitted

July 2, 2015

First Posted

July 22, 2015

Study Start

January 1, 2015

Primary Completion

March 1, 2016

Study Completion

March 1, 2016

Last Updated

July 22, 2015

Record last verified: 2015-07

Locations